Biotech Values

[DewDiligence]

MNTA – Omnitrope fallout: Based on today’s trading only, the largest benefactor of the FDA’s decision appears to be MNTA, up 7%.

I thought MNTA would be up even more on today’s news because the FDA’s approval of Omnitrope would seem to lessen the doubt surrounding the generic Lovenox application submitted by MNTA and NVS. Even though the generic Lovenox application is an ANDA rather than a 505b2 submission, the FDA may be worried about getting sued again if it doesn’t behave and puts up more silly excuses for letting an application languish.